📋 Tender Overview
Scope :
The Novo Nordisk Foundation Cellerator is set to become operational in 2027.
The Novo Nordisk Foundation, the philanthropic arm of pharmaceutical company Novo Nordisk, is developing a new advanced laboratory facility named Novo Nordisk Foundation Cellerator in Lyngby, Denmark, for the development and manufacture of cell therapies.
The Cellerator is established as a limited liability company and is wholly owned and funded by the Novo Nordisk Foundation.
With an investment of up to DKr950m ($136.2m), the facility will offer services ranging from process development to good manufacturing practice (GMP) manufacturing, product release, and regulatory support.
The Cellerator will cater to both public and private entities from academia, biotech, and the pharmaceutical industry. It will be the first large-scale production site in Denmark to offer such a comprehensive range of expertise and services.
Construction on the facility is scheduled to begin in mid-2024, and operations are expected to begin in 2027.
Location
The Cellerator will be situated within the Technical University of Denmark (DTU) in Lyngby, leveraging the university’s cell manufacturing and infrastructure expertise.
The strategic location fosters synergies with the DTU’s research, education, and innovation activities in health tech and biotechnology, benefiting from collaborations with startups and established companies.
Novo Nordisk Foundation Cellerator details
The Cellerator will house a process development and GMP facility tailored to the specific needs of cell therapy services.
The facility will be equipped with automation and modern technology to support various cell therapy types, including those derived from embryonic, induced pluripotent, and adult stem cells.
It will focus on developing cell therapies that have shown success in animal trials and manufacturing them at scale for early clinical trials. Furthermore, the facility will have built-in flexibility to respond to changing demands in the field.
Cell therapy represents a transformative approach to treating chronic diseases by using living cells to either repair or replace damaged tissues and cells.
Despite promising laboratory results, many potential therapies do not progress to human trials due to challenges in development and large-scale manufacturing.
The Novo Nordisk Foundation Cellerator aims to bridge the gap by becoming Europe’s premier facility for producing cell therapies for clinical trials. It is expected to foster advancements that could revolutionise the treatment of chronic diseases and reshape healthcare.
The Cellerator will also provide a unique opportunity for researchers and students to translate cell technologies into treatments for a range of diseases such as chronic heart failure, Parkinson’s disease, kidney ailments, diabetes, and cancer.
Partners involved
The Cellerator will collaborate with reNEW, an international research centre specialising in
